News Standigm launched new AI driven drug discovery services to the industry

November 03, 2017

Standigm announced today that it has launched two AI-driven drug discovery services, Expander and Hunter. Expander is a service that new and better indications for customer’s in-house compounds. By using Expander service, pharmaceutical companies are now able to achieve a quick identification of a novel clinical use for their existing drugs with low cost and effort. Hunter, another service other than Expander, discovers repositioned lead compounds tailored to customer’s interest. Hunter is based on Standigm’s state-of-the-art AI technology and searches for potential drugs, protein targets to combat the specific diseases that our customers are interested in.  .

Event BIO-Europe 2017

October 16, 2017

Date : November 6–8, 2017
Location : Berlin, Germany
Jinhan Kim, Standigm CEO will speak at the Bio-Europe 2017 on November 7, 2017. Sang Ok Song, Standigm COO will also attend the meeting. Meet them in Berlin.

News Standigm agrees partnership with KIST to discover a new drug for Autism

September 13, 2017

Standigm and Korea institute of science and technology (KIST) announced a research collaboration to develop a new small molecule medicine for Autism. The drug candidates chosen by Standigm’s AI drug discovery technology will validate experimentally by using KIST’s animal models.